DNA methylation markers predict recurrence-free interval in triple-negative breast cancer.
Publication/Presentation Date
1-1-2020
Abstract
We lack tools to risk-stratify triple-negative breast cancer (TNBC). Our goal was to develop molecular tools to predict disease recurrence. Methylation array analysis was performed on 110 samples treated by locoregional therapy obtained from institutional cohorts. Discovered marker sets were then tested by Kaplan-Meier analyses in a prospectively collected TNBC cohort of 49 samples from the no-chemotherapy arms of IBCSG trials VIII and IX, and by logistic regression in a chemotherapy-treated cohort of 121 TNBCs from combined IBCSG trials and institutional repositories. High methylation was associated with shorter recurrence-free interval in the no-chemotherapy arm of the IBCSG studies, as well as in the chemotherapy-treated patients within the combined institutional and IBCSG chemotherapy cohorts (100 marker panel,
Volume
6
First Page
3
Last Page
3
ISSN
2374-4677
Published In/Presented At
Fackler, M. J., Cho, S., Cope, L., Gabrielson, E., Visvanathan, K., Wilsbach, K., Meir-Levi, D., Lynch, C. F., Marks, J., Geradts, J., Regan, M. M., Viale, G., Wolff, A. C., Sukumar, S., & Umbricht, C. B. (2020). DNA methylation markers predict recurrence-free interval in triple-negative breast cancer. NPJ breast cancer, 6, 3. https://doi.org/10.1038/s41523-020-0145-3
Disciplines
Medicine and Health Sciences
PubMedID
32025567
Department(s)
Department of Obstetrics and Gynecology, Department of Obstetrics and Gynecology Residents, Fellows and Residents
Document Type
Article